301258 深市 富士莱

                    苏州富士莱医药股份有限公司

                      2021 年度财务决算报告

        苏州富士莱医药股份有限公司（以下简称“公司”）2021 年 12 月 31 日的财

    务报表及相关报表附注已经容诚会计师事务所(特殊普通合伙)审计，并出具标准

    无保留意见的审计报告。现将 2021 年度财务决算情况报告如下：

        一、主要财务数据

                                            2021 年                2020 年            本年比上年增减

营业收入（元）                                521,695,665.95          476,848,910.66                9.40%

归属于上市公司股东的净利润（元）              120,201,415.72          141,052,780.56                -14.78%

归属于上市公司股东的扣除非经常性损益

的净利润（元）                                115,415,204.48          135,512,748.24                -14.83%

经营活动产生的现金流量净额（元）              199,729,417.14          166,849,476.85                19.71%

基本每股收益（元/股）                                  1.75                  2.05                -14.63%

稀释每股收益（元/股）                                  1.75                  2.05                -14.63%

加权平均净资产收益率                                17.61%                23.45%                -5.84%

                                          2021 年末              2020 年末        本年末比上年末增减

资产总额（元）                                970,306,076.54          788,252,254.49                23.10%

归属于上市公司股东的净资产（元）              742,839,394.81          622,637,979.09                19.31%

    二、公司财务状况

    （1）资产构成重大变动情况

                                                                                          单位：元

                      2021 年末                  2021 年初

                  金额    占总资产比例    金额      占总资产比  比重增减        重大变动说明

                                                          例

货币资金                                                                      主要原因是本期经营活动结余
              332,057,268.50      34.22%  98,092,918.55      12.44%    21.78% 资金及短期理财产品到期赎回

应收账款        85,459,927.55      8.81%  79,732,639.27      10.12%    -1.31%

存货            68,597,809.23      7.07%  60,115,286.78      7.63%    -0.56%

投资性房地产    2,564,091.40      0.26%  2,813,008.00      0.36%    -0.10%

固定资产      408,976,766.92      42.15% 364,022,634.45      46.18%    -4.03%

在建工程        12,171,837.93      1.25%  17,584,065.64      2.23%    -0.98%

短期借款        18,576,354.10      1.91%                              1.91%

合同负债        6,727,362.43      0.69%  3,491,022.53      0.44%    0.25%


    （2）产销量

  行业分类          项目            单位            2021 年          2020 年          同比增减

                销售量          吨                        869.35            741.42          17.25%

硫辛酸系列产品  生产量          吨                        2,106.87          1,479.89          42.37%

                库存量          吨                          98.15            82.97          18.30%

                销售量          吨                          43.46            41.79            4.00%

肌肽系列产品    生产量          吨                          30.84            59.26          -47.96%

                库存量          吨                          11.38            24.51          -53.57%

磷脂酰胆碱系列  销售量          吨                          63.04            75.09          -16.05%
产品            生产量          吨                          70.54            67.86            3.95%
                库存量          吨                          9.37              1.92          388.02%

    （3）收入、成本、毛利率状况

                                                                                          单位：元

                              2021 年                            2020 年                  同比增减

                      金额        占营业收入比重        金额        占营业收入比重

营业收入合计        521,695,665.95            100%    476,848,910.66            100%            9.40%

分行业

医药主营业务        511,664,000.06          98.08%    466,864,173.42          97.91%            9.60%

其他业务            10,031,665.89            1.92%      9,984,737.24            2.09%            0.47%

分产品

硫辛酸系列产品      412,125,346.14          79.00%    351,877,489.72          73.79%          17.12%

肌肽系列产品        55,590,569.58          10.66%      54,561,663.81          11.44%            1.89%

磷脂酰胆碱系列

产品                43,948,084.34            8.42%      60,425,019.89          12.67%          -27.27%

其他业务            10,031,665.89            1.92%      9,984,737.24            2.10%            0.47%

分地区

国外                355,714,983.67          68.18%    358,463,354.84          75.17%          -0.77%

国内                165,980,682.28          31.82%    118,385,555.82          24.83%          40.20%

分销售模式

直销                172,914,669.35          33.14%    162,762,213.21          34.13%            6.24%

经销                338,749,330.71          64.93%    304,101,960.21          63.77%          11.39%

其他业务            10,031,665.89            1.92%      9,984,737.24            2.09%            0.47%

    （4）费用状况

                                                                                          单位：元


                      2021 年          2020 年          同比增减                重大变动说明

销售费用              4,700,373.44      6,104,261.87          -23.00% 主要是